TNFRSF10B and familial pancreatic carcinoma: To determine how the bulk tumor responds to drozitumab when only a fraction of the cells expressed DR5, we investigated death receptor expression kinetics in vitro using both a commercial pancreatic cancer cell line and cells isolated from a PDX.